Literature DB >> 10893656

Patient acceptability of a new 3.0 ml pre-filled insulin pen.

P D'Eliseo1, J Blaauw, Z Milicević, J Wyatt, D A Ignaut, J K Malone.   

Abstract

The objective of these two studies was to assess patient acceptance and feature preferences of the new Lilly 3.0 ml pre-filled pen. A total of 701 patients with diabetes mellitus, who required insulin, were treated for 4-6 weeks with the pre-filled pen. Patient acceptance and treatment preferences were assessed by a questionnaire completed at the end of the study period. Patients with type 1 or type 2 diabetes mellitus from South Africa (n = 371) and Croatia (n = 330) were enrolled in the study. The mean age was 51.6 years (range: 18-81), and gender was 359 males and 342 females. Prior to the study, patients in South Africa (SA) had used the Novo Actraphane (Novo Nordisk, Bagsvaerd, Denmark) pen set, and patients in Croatia (C) had used NovoPen 1 or 2 (Novo Nordisk, Bagsvaerd, Denmark) (38.8%), NovoPen 3 (Novo Nordisk, Bagsvaerd, Denmark) (28.8%), B-D Pen (Becton-Dickinson, Franklin Lakes, New Jersey, USA) (18.8%), needle/syringe (10.0%), oral hypoglycaemic agents (2.1%), or unknown (1.5%). The new Lilly 3.0 ml pre-filled pen features that were rated by respondents as good to excellent on a five-point rating scale included: cartridge visibility (C = 94%, SA = 83%), ease of dose correction (C = 92%, SA = 85%), dialling of the dose (C = 89%, SA = 81%), turning of the dose knob (C = 84%, SA = 82%) and attaching needles (C = 92%, SA = 78%). Most respondents (C = 78%, SA = 75%) preferred single-unit versus two-unit dosage increments. Overall, 76% of patients in Croatia and 80% in South Africa preferred the Lilly 3.0 ml pre-filled pen to their previous delivery device; 84% and 87% of patients, respectively, would recommend the pen to another patient. Also, the majority of patients in both trials rated the new Lilly 3.0 ml pre-filled pen as being more convenient and easier to use, and indicated that it represented a significant or modest improvement over their previous insulin injection method. The results of this study confirm that the new Lilly 3.0 ml pre-filled pen is widely accepted and preferred by patients using both reusable and pre-filled devices.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893656

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  7 in total

1.  Performance of a new reusable insulin pen.

Authors:  Alfred Penfornis
Journal:  Diabetes Technol Ther       Date:  2011-02-03       Impact factor: 6.118

2.  Do different body colors and labels of insulin pens enhance a patient's ability to correctly identify pens for injecting long-acting versus short-acting insulins?

Authors:  Mark Lefkowitz
Journal:  J Diabetes Sci Technol       Date:  2011-01-01

3.  Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study.

Authors:  Carlos Martín de Argila; Julio Ponce; Emilio Márquez; M José Plazas; Jordi Galván; Joan Heras; Joana Porcel
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.

Authors:  Udo Stauder; Diplom Enginee; Hina Elton; Alfred Penfornis; Steve Edelman
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

Review 5.  Patient preferences for the treatment of type 2 diabetes: a scoping review.

Authors:  Susan M Joy; Emily Little; Nisa M Maruthur; Tanjala S Purnell; John F P Bridges
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

6.  Psychometric assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone.

Authors:  Andreas M Pleil; Miriam Kimel; Julie McCormack; Natasa Rajicic; Judith Hey-Hadavi
Journal:  Health Qual Life Outcomes       Date:  2012-10-09       Impact factor: 3.186

7.  Initial experience and evaluation of reusable insulin pen devices among patients with diabetes in emerging countries.

Authors:  Balduino Tschiedel; Oscar Almeida; Jennifer Redfearn; Frank Flacke
Journal:  Diabetes Ther       Date:  2014-09-12       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.